Schuster Timothy G, Marcovich Robert, Sheffield Jacqueline, Montie James E, Lee Cheryl T
Department of Urology, University of Michigan Hospitals, Ann Arbor, MI 48109-0330, USA.
Urology. 2003 Feb;61(2):342-7; discussion 347. doi: 10.1016/s0090-4295(02)02272-0.
To review our perioperative experience with patients presenting with high-risk bladder cancer who had undergone prior therapy for prostate cancer. With the increase in diagnosis and subsequent treatment of prostate cancer, more patients presenting with high-risk bladder cancer have undergone prior therapy for prostate cancer. Radical cystectomy in these patients can be technically challenging and may be associated with added morbidity.
A retrospective review of 458 patients treated with radical cystectomy between January 1993 and January 2002 revealed 29 patients (mean age 72 years) who had received definitive treatment for prostate cancer prior to cystectomy for bladder carcinoma. The initial treatment in this cohort was radical prostatectomy or external beam radiotherapy in 12 (41%) and 17 (59%) men, respectively. Cystectomy was performed for transitional cell carcinoma in 25 (86%), small cell carcinoma in 2 (6%), and sarcoma in 2 (6%) patients.
At the time of cystectomy, the mean blood loss was 1175 mL (range 275 to 3500), and the median length of hospitalization was 8 days (range 4 to 23). No intraoperative or perioperative deaths occurred in this cohort. Twenty-seven early complications were identified in 16 (55%) of 29 patients; no rectal injuries occurred. Patients with prior radiotherapy had a higher rate of extravesical bladder carcinoma (60%) than those patients treated with prior prostatectomy (33%). An orthotopic neobladder diversion was created in 5 patients (17%).
Patients with bladder cancer previously treated for prostate cancer with external beam radiotherapy or radical prostatectomy have an increased risk of perioperative complications compared with patients undergoing cystectomy without prior therapy. This risk is not prohibitive, and radical cystectomy should remain the treatment of choice for high-risk bladder cancer in this population. Furthermore, orthotopic urinary diversion may be a reasonable option and should be considered in select patients.
回顾我们对曾接受前列腺癌治疗的高危膀胱癌患者的围手术期经验。随着前列腺癌诊断及后续治疗的增加,更多高危膀胱癌患者曾接受过前列腺癌治疗。对这些患者行根治性膀胱切除术在技术上具有挑战性,且可能会增加发病率。
对1993年1月至2002年1月间接受根治性膀胱切除术的458例患者进行回顾性分析,发现29例(平均年龄72岁)在因膀胱癌行膀胱切除术之前已接受前列腺癌的确定性治疗。该队列中的初始治疗分别为12例(41%)男性接受根治性前列腺切除术和17例(59%)男性接受外照射放疗。25例(86%)患者因移行细胞癌行膀胱切除术,2例(6%)因小细胞癌,2例(6%)因肉瘤。
膀胱切除术时,平均失血量为1175毫升(范围275至3500毫升),中位住院时间为8天(范围4至23天)。该队列中无术中或围手术期死亡发生。29例患者中有16例(55%)出现27例早期并发症;未发生直肠损伤。与接受过前列腺切除术的患者(33%)相比,接受过放疗的患者膀胱外膀胱癌发生率更高(60%)。5例患者(17%)行原位新膀胱改道术。
与未接受过先前治疗而行膀胱切除术的患者相比,曾接受外照射放疗或根治性前列腺切除术治疗前列腺癌的膀胱癌患者围手术期并发症风险增加。这种风险并非不可接受,根治性膀胱切除术仍应是该人群高危膀胱癌的首选治疗方法。此外,原位尿流改道可能是一种合理的选择,应在特定患者中考虑。